Please assess the completion status of the following clinical trial:

Trial Title: Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects at the time of enrollment.~* Each subject will give informed consent to participate in this study and agrees to the treatment protocol.~* Each subject will be interviewed regarding hearing and health to reveal any history of hearing loss, tinnitus, known ear pathology, use of any potentially ototoxic medications (i.e. diuretics, minocycline).~* Non-occupational sound exposure (e.g., concerts, firearms, fireworks, power tools) will be avoided during the 24-hour period preceding baseline testing and throughout the duration of the study.~* Subjects will have vital signs (i.e., heart rate, blood pressure, respirations, temperature) within normal limits upon medical examination.~* Subjects must have normal audiologic assessment at baseline consisting of:~* Baseline audiometric evaluation confirms that subjects have symmetric hearing with air conduction thresholds no worse than 25 decibels of Hearing Loss (dBHL) at frequencies between 0.25 to 8 kilo Hertz (kHz) bilaterally.~* No significant threshold asymmetry (i.e. greater than 15 dB) between the ears at any tested frequency.~* No significant air-bone gaps (i.e. greater than 10 dB)~* Type A tympanograms bilaterally, defined as a range of -140 to +40 dekaPascals (daPa) based on the 90% range for adults (Margolis and Hunter 2000)~Exclusion Criteria:~* • Subjects with abnormal hearing levels \> 25 dBHL at any tested frequency (250, 500, 1000, 2000, 3000, 4000, 6000 and 8000 Hz) for either ear.~* Exposure to any duration of non-occupational high-level sound (e.g., concerts, firearms, fireworks, power tools) during the 24 hour period preceding baseline audiometric testing as revealed in the subject questionnaire or during the medical examination.~* Pathology of the external ear discovered upon otoscopic examination.~* Pathology of the middle ear revealed by otoscopic examination, abnormal tympanometry, or reported history of middle ear problems.~* Pathology of the inner ear or auditory nerve as revealed by reported history.~* Subject complaints of aural pain, pressure, fullness, or drainage.~* Subjects testing positive for pregnancy will be excluded from the study.~* Subjects with other medical/health issues that would preclude voluntary participation in a drug study may be excluded at the discretion of the Principal Investigator.~* Subjects that have previously received any known potentially ototoxic medication. This includes, but is not limited to, high dose salicylates (\>2 g/day), platinum-based chemotherapeutics and aminoglycoside antibiotics, such as streptomycin, gentamicin,tobramycin, amikacin, neomycin, and netilmycin.~* Subjects that are currently using of any potentially ototoxic medications (i.e. diuretics or minocycline).~* Subjects that have received any investigational treatment (drug or device) in the six months prior to this study.~* Subjects exhibiting or self-reporting shortness of breath, wheezing, coughing, or hemoptysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 31 Years
- Healthy Volunteers: t

Study Arms:
- SPI-1005 Low dose (Type: ACTIVE_COMPARATOR): 200mg SPI-1005, capsule, bid, po, x4d
- SPI-1005 Middle Dose (Type: ACTIVE_COMPARATOR): 400mg SPI-1005, capsule, bid, po, x4d
- SPI-1005 High Dose (Type: ACTIVE_COMPARATOR): 600mg SPI-1005, capsule, bid, po, x4d
- Placebo (Type: PLACEBO_COMPARATOR): 0mg SPI-1005, capsule, bid, po, x4d

Based on this trial design, predict the completion outcome and termination type (if applicable).